Effects of Finerenone on Renal Hemodynamics and Oxidative Stress

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508266-15-00

Acronym

FINE

Enrollment

Registered

2023-12-19

Start date

2024-01-18

Completion date

2025-11-25

Last updated

2024-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Brief summary

Primary endpoint is to analyse the impact of finerenone on the oxidative stress level of renal vasculature by the increase of renal perfusion following vitamin C infusion compared to placebo

Interventions

DRUGKerendia 10 mg film coated tablets

DRUGPlacebo: film-coated tablet without active substance for oral use

DRUGAMINOHIPPURIC ACID

DRUGACCUPAQUE™ 350 Injektionslösung oder Lösung zum Einnehmen

DRUGKerendia 20 mg film-coated tablets

DRUGL-ARGININE HYDROCHLORIDE

DRUGCentricor® Vitamin C Ampullen 100 mg/ml Injektionslösung

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Primary endpoint is to analyse the impact of finerenone on the oxidative stress level of renal vasculature by the increase of renal perfusion following vitamin C infusion compared to placebo	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026